Search research articles
Contact Us
Filters
Showing results (31-40 of 86) with videos related to
Page
of 9
Sort By:
Cancer
|
April 19, 2018
Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial
Margaret K Guerriero, Mary W Redman, Kelsey K Baker, et al.
Clinical Lung Cancer
|
November 10, 2021
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC
Fred R Hirsch, Mary W Redman, James Moon, et al.
Cancer
|
April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)
Gerold Bepler, Ralph G Zinner, James Moon, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine
|
August 21, 2015
Cognitive Behavioral Stress Management for Healthy Women at Risk for Breast Cancer: a Novel Application of a Proven Intervention
Bonnie A McGregor, Emily D Dolan, Karly M Murphy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2013
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536
Edward S Kim, James Moon, Roy S Herbst, et al.
Pancreas
|
June 9, 2021
DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma
Amy E Chang, Marc R Radke, David B Zhen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Philip C Mack, Jieling Miao, Mary W Redman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
Primo N Lara, Ronald Natale, John Crowley, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2019
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Martin J Edelman, Mary W Redman, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy
Carol M Moinpour, Katherine A Hayden, Joseph M Unger, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 86) with videos related to
Sort By:
Page
of 9
Cancer
|
April 19, 2018
Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial
Margaret K Guerriero, Mary W Redman, Kelsey K Baker, et al.
Clinical Lung Cancer
|
November 10, 2021
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC
Fred R Hirsch, Mary W Redman, James Moon, et al.
Cancer
|
April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)
Gerold Bepler, Ralph G Zinner, James Moon, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine
|
August 21, 2015
Cognitive Behavioral Stress Management for Healthy Women at Risk for Breast Cancer: a Novel Application of a Proven Intervention
Bonnie A McGregor, Emily D Dolan, Karly M Murphy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2013
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536
Edward S Kim, James Moon, Roy S Herbst, et al.
Pancreas
|
June 9, 2021
DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma
Amy E Chang, Marc R Radke, David B Zhen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2022
Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)
Philip C Mack, Jieling Miao, Mary W Redman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
Primo N Lara, Ronald Natale, John Crowley, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2019
SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
Martin J Edelman, Mary W Redman, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 2008
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy
Carol M Moinpour, Katherine A Hayden, Joseph M Unger, et al.
Page
of 9